Efficacy Combined Fecal Immunochemical Test-Sigmoidoscopy for the Detection of Advanced Colorectal Neoplasia

NCT ID: NCT01767870

Last Updated: 2013-01-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

5282 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-08-31

Study Completion Date

2015-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the efficacy and cost-effectiveness of fecal immunochemical test combined with sigmoidoscopy (FITS) for the detection of advanced colorectal neoplasia compared to colonoscopy.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The investigators will evaluate the efficacy of FITS for the detection of advanced colorectal neoplasia compared to colonoscopy. This study was designed as multicenter randomized interventional study. The expected period are 36months. A total 13 tertiary hospitals will participate in the study.

Subjects will be randomly allocated to FITS group and colonoscopy group. Subjects who undergo FITS will be performed by following colonoscopy to confirm the efficacy of FITS. In colonoscopy group, subjects as a control group would be performed colonoscopy.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Colorectal Adenoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

FIT-Sigmoidoscopy

This arm (FIT-Sigmoidoscopy) will take fecal immunochemical test (FIT) followed by sigmoidoscopy for evaluation of advanced colorectal adenoma detection rate. Immediately after sigmoidoscopy, a total colonoscopy will be performed as a standard method for advanced colorectal adenoma detection.

Group Type EXPERIMENTAL

FIT-sigmoidoscopy

Intervention Type PROCEDURE

Advanced colorectal adenoma detection by fecal immunochemical test with sigmoidoscopy

Colonoscopy

This arm (Colonoscopy) will take a total colonoscopy as a control group that will represent the efficacy of colonoscopy for advanced colorectal adenoma detection rate.

Group Type EXPERIMENTAL

Colonoscopy

Intervention Type PROCEDURE

Advanced colorectal adenoma detection by colonoscopy

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

FIT-sigmoidoscopy

Advanced colorectal adenoma detection by fecal immunochemical test with sigmoidoscopy

Intervention Type PROCEDURE

Colonoscopy

Advanced colorectal adenoma detection by colonoscopy

Intervention Type PROCEDURE

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

FITS sigmoidoscopy

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Asymptomatic subjects aged 45 - 75 years
* Subjects who will give the written consent

Exclusion Criteria

* Subjects with past history of colorectal cancer
* Subjects with familial histories of familial adenomatous polyposis(FAP) or Hereditary nonpolyposis colorectal cancer(HNPCC)
* Subjects with familial history of colorectal cancer more than 2 familial member in direct line
* Subjects with inflammatory bowel disease(IBD)
* Subjects with more than 3 point of American Society of Anesthesiologists (ASA) physical classification
* Subjects with past history of colectomy
* Subjects with history of colonoscopy within 5 years
* Subjects with history of sigmoidoscopy within 3 years
* Subjects with history of CT colonoscopy within 10 years
* Subjects with symptoms that could present the colorectal cancer such as hematochezia, melena, weight loss more than 10kg/6months
Minimum Eligible Age

45 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Yonsei University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Hyun-Soo Kim, M.D., ph D.

Role: STUDY_CHAIR

Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea

Hong Jun Park, M.D.

Role: STUDY_DIRECTOR

Department of Internal Medicine, Yonsei University Wonju College of Medicine, Wonju, Republic of Korea

Hwang Choi, M.D., ph D.

Role: PRINCIPAL_INVESTIGATOR

Department of Internal Medicine, The Catholic University of Korea College of Medicine, Incheon, Korea

Jeong Seon Ji, M.D.

Role: PRINCIPAL_INVESTIGATOR

Department of Internal Medicine, The Catholic University of Korea College of Medicine, Incheon, Korea

Young Suk Cho, M.D.

Role: PRINCIPAL_INVESTIGATOR

Department of Internal Medicine, the Catholic University of Korea, Uijeongbu, Korea

Young-Eun Joo, M.D., ph D.

Role: PRINCIPAL_INVESTIGATOR

Departments of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea

Jeong Eun Shin, M.D.

Role: PRINCIPAL_INVESTIGATOR

Departments of Internal Medicine, Dankook University College of Medicine, Cheonan, Korea

Eun Soo Kim, M.D.

Role: PRINCIPAL_INVESTIGATOR

Departments of Internal Medicine, Kyungpook National University School of Medicine, Korea

Seong-Eun Kim, M.D.

Role: PRINCIPAL_INVESTIGATOR

Departments of Internal Medicine, Ewha Womans University School of Medicine, Seoul, Korea

Dong Il Park, M.D., ph D.

Role: PRINCIPAL_INVESTIGATOR

Departments of Internal Medicine, Sungkyunkwan University College of Medicine, Seoul, Korea

Jae Myung Cha, M.D., ph D.

Role: PRINCIPAL_INVESTIGATOR

Departments of Internal Medicine, Kyung Hee University College of Medicine, Hanam, Korea

Sung Noh Hong, M.D.

Role: PRINCIPAL_INVESTIGATOR

Departments of Internal Medicine, Konkuk University School of Medicine, Seoul, Korea

Seun-Ja Park, M.D., ph D.

Role: PRINCIPAL_INVESTIGATOR

Departments of Internal Medicine, Kosin University College of Medicine, Busan, Korea

Hyun Gun Kim, M.D.

Role: PRINCIPAL_INVESTIGATOR

Departments of Internal Medicine, Soonchunhyang University College of Medicine, Seoul, Korea

Sung Pil Hong, M.D.

Role: PRINCIPAL_INVESTIGATOR

Departments of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea

Jae Hak Kim, M.D.

Role: PRINCIPAL_INVESTIGATOR

Departments of Internal Medicine, Dongguk University Ilsan Hospital, Ilsan, Korea

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Wonju Christian Hospital

Wŏnju, , South Korea

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

South Korea

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Hyun-Soo Kim, M.D., ph D.

Role: CONTACT

+82-33-741-1224

Hong Jun Park, M.D.

Role: CONTACT

+82-33-741-1226

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Hyun-Soo Kim, M.D., ph D.

Role: primary

+82-33-741-1224

Hong Jun Park, M.D.

Role: backup

+82-33-741-1226

References

Explore related publications, articles, or registry entries linked to this study.

Mandel JS, Church TR, Bond JH, Ederer F, Geisser MS, Mongin SJ, Snover DC, Schuman LM. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med. 2000 Nov 30;343(22):1603-7. doi: 10.1056/NEJM200011303432203.

Reference Type RESULT
PMID: 11096167 (View on PubMed)

Rozen P, Levi Z, Hazazi R, Waked A, Vilkin A, Maoz E, Birkenfeld S, Niv Y. Quantitative colonoscopic evaluation of relative efficiencies of an immunochemical faecal occult blood test and a sensitive guaiac test for detecting significant colorectal neoplasms. Aliment Pharmacol Ther. 2009 Feb 15;29(4):450-7. doi: 10.1111/j.1365-2036.2008.03898.x. Epub 2008 Nov 17.

Reference Type RESULT
PMID: 19035980 (View on PubMed)

Wong WM, Lam SK, Cheung KL, Tong TS, Rozen P, Young GP, Chu KW, Ho J, Law WL, Tung HM, Choi HK, Lee YM, Lai KC, Hu WH, Chan CK, Yuen MF, Wong BC. Evaluation of an automated immunochemical fecal occult blood test for colorectal neoplasia detection in a Chinese population. Cancer. 2003 May 15;97(10):2420-4. doi: 10.1002/cncr.11369.

Reference Type RESULT
PMID: 12733140 (View on PubMed)

Launoy GD, Bertrand HJ, Berchi C, Talbourdet VY, Guizard AV, Bouvier VM, Caces ER. Evaluation of an immunochemical fecal occult blood test with automated reading in screening for colorectal cancer in a general average-risk population. Int J Cancer. 2005 Jun 20;115(3):493-6. doi: 10.1002/ijc.20921.

Reference Type RESULT
PMID: 15700317 (View on PubMed)

Whitlock EP, Lin JS, Liles E, Beil TL, Fu R. Screening for colorectal cancer: a targeted, updated systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2008 Nov 4;149(9):638-58. doi: 10.7326/0003-4819-149-9-200811040-00245. Epub 2008 Oct 6.

Reference Type RESULT
PMID: 18838718 (View on PubMed)

Schoen RE, Pinsky PF, Weissfeld JL, Yokochi LA, Church T, Laiyemo AO, Bresalier R, Andriole GL, Buys SS, Crawford ED, Fouad MN, Isaacs C, Johnson CC, Reding DJ, O'Brien B, Carrick DM, Wright P, Riley TL, Purdue MP, Izmirlian G, Kramer BS, Miller AB, Gohagan JK, Prorok PC, Berg CD; PLCO Project Team. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med. 2012 Jun 21;366(25):2345-57. doi: 10.1056/NEJMoa1114635. Epub 2012 May 21.

Reference Type RESULT
PMID: 22612596 (View on PubMed)

Lieberman DA, Weiss DG; Veterans Affairs Cooperative Study Group 380. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med. 2001 Aug 23;345(8):555-60. doi: 10.1056/NEJMoa010328.

Reference Type RESULT
PMID: 11529208 (View on PubMed)

Kato J, Morikawa T, Kuriyama M, Yamaji Y, Wada R, Mitsushima T, Yamamoto K. Combination of sigmoidoscopy and a fecal immunochemical test to detect proximal colon neoplasia. Clin Gastroenterol Hepatol. 2009 Dec;7(12):1341-6. doi: 10.1016/j.cgh.2009.04.025. Epub 2009 May 6.

Reference Type RESULT
PMID: 19426835 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://www.ncc.re.kr

We use the web-based e-Case report form (CRF) system for collection of data from different area, named 'eVLEOS' system which servers are located on Korean National Cancer Center

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CR312033

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.